Remyelination is a term for the re-generation of the nerve's myelin sheath, damaged in many diseases such as multiple sclerosis (MS) and the leukodystrophies. Remyelination is a subject of active medical research.
What if the missing ‘environmental’ factor in some of our deadliest neurological diseases were really written in our genome?
Multiple sclerosis is an autoimmune disease that affects more than 2.3 million people worldwide. This debilitating condition periodically shutters communication between the brain and other parts of the body, resulting in symptoms that range from numbness and tingling in the arms and legs to blindness and paralysis.
Researchers have discovered that in adult stem cells, the activation of a specific transcription factor induces pathological quiescence and that this is deactivated in MS.
Nerve cells stripped of their insulation can no longer carry vital information, leading to the numbness, weakness and vision problems often associated with multiple sclerosis. A new study shows an overlooked source may be able to replace that lost insulation and provide a new way to treat diseases like MS.
Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.
Research published today in the journal Nature provides new understanding about how drugs can repair damaged brain cells that cause disability in patients with multiple sclerosis.
For decades, clinicians treating multiple sclerosis have interpreted the appearance of new or expanding brain lesions on magnetic resonance imaging scans as a sign that a patient's disease is getting worse.
Celgene Corporation today announced that it has received a Refusal to File letter from the United States Food and Drug Administration regarding its New Drug Application for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis.
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies.
Longevity Biotech, Inc. has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society's commercial research funding program, to evaluate LBT-3627 in preclinical models as a potential disease-modifying therapeutic agent.
In the central nervous system of humans and all other mammals, a vital insulating sheath composed of lipids and proteins around nerve fibers helps speed the electrical signals or nerve impulses that direct our bodies to walk, talk, breathe, swallow or perform any routine physical act.
In a remarkably rapid translation of laboratory research findings into a treatment with the potential to benefit patients, UC San Francisco scientists have successfully completed a Phase II clinical trial showing that an FDA-approved antihistamine restores nervous system function in patients with chronic multiple sclerosis (MS).
Brain functions are maintained by the neural network. Neural network is formed by the connection between the neurite, and this connection is supported by the wrapping of myelin.
Through their pattern of firing, neurons influence the behavior of the cells that upon maturation will provide insulation of neuronal axons, according to a new study publishing 22 August in the open access journal PLOS Biology by Balint Nagy, Maria Kukley and colleagues at the University of Tübingen, Germany.
Multiple sclerosis is an autoimmune disease of the central nervous system that affects nearly 2.3 million people worldwide.
Researchers have identified a gene (CYFIP2) associated with binge eating. This finding represents one of the first examples of a genome-wide significant genetic factor to be identified for binge eating in model organisms or humans.
Physicians at Rush University Medical Center became the first in Illinois to inject AST-OPC1 (oligodendrocyte progenitor cells), an experimental treatment, into the damaged cervical spine of a recently paralyzed man as part of a multicenter clinical trial.
Demyelinating diseases, such as multiple sclerosis and leukodystrophy, are characterized by damage to the protective myelin sheath that surrounds the axons of neurons.
To me the most exciting aspect of pre-clinical imaging is its broad range, from very basic science up to applied science. You deal with a range of disciplines including biology, chemistry, physics, biochemistry, biophysics, cell biology and of course medicine, as the aim is the translation of research to humans.
Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.